Imstem Biotechnology: AgeX Therapeutics, ImStem Biotechnology sign non-binding letter of intent regarding investigational MSC candidate IMS001 for Covid-19

AgeX and ImStem are co-operating to finalize financial terms and other provisions of a license agreement. ImStem has previously used AgeX ESI 053 to derive the ImStem IMS001The post AgeX Therapeutics, ImStem Biotechnology sign non-binding letter of intent regarding investigational MSC candidate IMS001 for Covid-19 appeared first on Pharmaceutical Business review.